SEC Form 4 · accession 0001104659-18-072099
Neos Therapeutics, Inc. · NEOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald W. McLaughlin
Officer — Chief Executive Officer · Director
Period of report
Dec 6, 2018
Accepted (ET)
Dec 10, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001467652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 6, 2018 | P | 17,097 | $2.1126 | A | 24,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.045 to $2.16, inclusive. The reporting person undertakes to provide Neos Therapeutics, Inc., any security holder of Neos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.